Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Smith & Nephew : Timing of Smith+Nephew Third Quarter 2020 Trading Report

10/12/2020 | 10:06am EST

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, will announce its trading report for the third quarter on 29 October 2020 at 7.00am GMT / 3.00am EDT.

This will be followed by a conference call for financial analysts at 8.30am GMT / 4.30am EDT, details of which can be found on the Smith+Nephew website at www.smith-nephew.com/results.


Andrew Swift

Tel: +44 (0) 1923 477433

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SMITH & NEPHEW PLC
11/23SMITH & NEPHEW : SCOTUS To Decide Constitutionality Of PTAB Judge Appointments
11/20SMITH & NEPHEW : Investor presentation October - December 2020
11/20SMITH & NEPHEW : What Arthrex Could Mean For The PTAB Going Forward
11/18SMITH & NEPHEW : New data shows Smith+Nephew's NOVOSTITCH Meniscal Repair System..
11/13ARTHREX : Who Are You Calling Inferior?
11/06SMITH & NEPHEW : +Nephew adds patient selection and care-pathway optimization to..
10/31SMITH & NEPHEW PLC : Monthly statement on outstanding equity shares and voting r..
10/29SMITH & NEPHEW : +Nephew revenue lifted by recovery in elective surgery demand
10/29SMITH & NEPHEW : 3Q Underlying Revenue Improved After Virus Hit
10/29SMITH & NEPHEW : +Nephew Third Quarter 2020 Trading Report
More news
Financials (USD)
Sales 2020 4 694 M - -
Net income 2020 389 M - -
Net Debt 2020 1 633 M - -
P/E ratio 2020 44,9x
Yield 2020 1,52%
Capitalization 16 704 M 16 656 M -
EV / Sales 2020 3,91x
EV / Sales 2021 3,38x
Nbr of Employees 17 500
Free-Float 98,7%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 15
Average target price 21,24 $
Last Close Price 19,11 $
Spread / Highest target 40,3%
Spread / Average Target 11,1%
Spread / Lowest Target -30,3%
EPS Revisions
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors